| AveXis, Inc. | 8,700 | AveXis’ lead product candidate, AVXS-101, expected to enhance Novartis’s position as a gene therapy and neuroscience leader | Novartis AG | Acquisition | United States |
| Merck KGaA | 4,200 | This acquisition enables P&G to expand its successful consumer health care business by adding a fast-growing portfolio of differentiated, physician-supported brands across a broad geographic footprint. It also provides P&G with strong health care commercial and supply capabilities, deep technical mastery and proven consumer health care leadership that will complement P&G's existing consumer Health Care capabilities and brands such as Vicks, Metamucil, Pepto-Bismol, Crest and Oral-B. | Procter & Gamble (P&G) | Acquisition | Germany |
| Cellectis | 2,800 | Earlier today, Allogene and Pfizer announced that the two companies have entered into an asset contribution agreement for Pfizer’s allogeneic CAR T-cell therapy portfolio, which includes 16 preclinical assets and UCART19. | Allogene Therapeutics, Inc. | Collaboration & License Agreement | France |
| Shire PLC | 2,400 | The transaction covers the transfer of Shire’s Oncology business including in-market products ONCASPAR® (pegaspargase), a component of multi-agent treatment for acute lymphoblastic leukemia (ALL) and ex-U.S. rights to ONIVYDE® (irinotecan pegylated liposomal formulation), a component of multi-agent treatment for metastatic pancreatic cancer post gemcitabine based therapy. | Servier | Acquisition | Ireland |
| Sound Inpatient Physicians Holdings (Fresenius Medical Care) | 2,150 | Fresenius Medical Care, the world’s largest provider of dialysis products and services, today has signed a definitive agreement to divest its controlling interest in Sound Inpatient Physicians Holdings, LLC (“Sound”) to an investment consortium led by Summit Partners, L.P. for total transaction proceeds of $2.15 billion (EUR 1.76 billion). The divestment is expected to generate a pre-tax book gain of approximately EUR 800 million. | Fresenius Medical Care | Divestment | United States |
| Mylan Inc. | 2,098 | The Notes will be issued by Mylan Inc. and guaranteed by Mylan N.V., and Mylan intends to use the net proceeds from the offering to redeem $1.5 billion aggregate principal amount of outstanding notes due in 2018 and 2019. Mylan also intends to repay €500 million aggregate principal amount of notes due in November 2018 at maturity. Closing of the offering is expected on April 9, 2018. | Mylan N.V. | Bond Offering | United States |
| Curo Health Services | 1,400 | Curo is a hospice operator with 245 outlets in 22 states. Humana will hold a 40% minority interest in the company when the deal is completed, expected by summer of 2018. The consortium is in the midst of acquiring the Kindred at Home Division of Kindred Healthcare Inc. the largest home health provider and second largest hospice operator in the U.S. | Humana | Acquisition | United States |
| OSE Immunotherapeutics SA | 1,196 | Boehringer Ingelheim and OSE Immunotherapeutics enter into a global license and collaboration agreement in immuno-oncology to develop OSE-172, a novel checkpoint inhibitor antibody targeting myeloid lineage cells. Assuming all milestones are met, OSE stands to receive more than €1.1 billion. OSE-172, an anti-SIRP-alpha monoclonal antibody, is currently in late stage preclinical development with potential in various cancers. | Boehringer Ingelheim | License Agreement | France |
| Analogic Corporation | 1,100 | This 10-month, comprehensive process resulted in today’s transaction with Altaris that provides stockholders with immediate, substantial, and certain cash value. The Board strongly believes that a transaction with a buyer with strategic assets like Altaris provides maximum value for and is in the best interest of Analogic stockholders. | Altaris Capital Partners, LLC, | Merger Agreement | United States |
| GE Healthcare (API Healthcare) | 1,050 | To acquire the Enterprise Financial Management (Revenue-Cycle, Centricity Business), Ambulatory Care Management (Centricity Practice Solution) and Workforce Management (formerly API Healthcare) | Veritas Capital | Acquisition | United States |
| Ionis Pharmaceuticals | 1,000 | Transaction builds upon the productive collaboration that produced SPINRAZA® as well as two antisense drug candidates currently in the clinic, with the potential to advance up to seven more drug candidates to the clinic within the next two years. | Biogen, Inc. | Collaboration | United States |
| Wilson Therapeutics AB | 855 | WTX101 is in Phase 3 Development as a Novel Treatment for Wilson Disease, a Rare, Genetic, and Chronic Copper-Mediated Liver Disorder | Alexion Pharmaceuticals, Inc | Acquisition | Sweden |
| Covance Food Solutions (LabCorp®) | 670 | Covance Food Solutions, which became part of LabCorp through its 2015 acquisition of Covance, offers an extensive set of routine and specialized laboratory testing and consulting services focused on ensuring product safety, quality and adherence to targeted internal and external standards for existing and in-development food, beverage and supplement products. | Eurofins Scientific (EUFI.PA) | Acquisition | United States |
| Sigilon Therapeutics | 473 | Sigilon will create proprietary products comprised of induced pluripotent stem cells, a type of stem cell derived from adult cells, engineered into differentiated insulin-producing pancreatic beta cells and encapsulated using Sigilon's Afibromer drug delivery system. The goal of these products will be to restore insulin production over sustained periods, without triggering an immune reaction. Encapsulated cell therapy is an emerging area of biopharmaceutical research that aims to unleash the th | Eli Lilly and Company | Collaboration | United States |
| EpiDestiny Inc. | 400 | EpiDestiny recently completed a phase 1 trial with EPI01 in SCD patients demonstrating increased HbF expression and safety after eight weeks of administration in a small patient cohort. The clinical observations demonstrated the potential for EPI01 to serve as a safe and highly meaningful disease-modifying therapy for SCD.n | Novo Nordisk A/S | License Agreement | United States |
| NextGen Healthcare (Quality Systems, Inc.) | 400 | This amended facility matures on March 29, 2023 and replaces NextGen Healthcare's prior $250 million facility. In addition to the increase from $250 million to $300 million in potential revolving credit commitments and/or term loans, the facility includes a $100 million accordion feature, which could accommodate additional borrowing up to $400 million in the aggregate. | | Credit Facility | United States |
| Industrial Development Authority (IDA), Ireland | 388 | This state-of-the-art "facility of the future" will be built upon the novel approach WuXi Biologics has pioneered deploying multiple single-use bioreactors for commercial biomanufacturing and is also designed to be able to run continuous bioprocessing, a next generation manufacturing technology to be first implemented globally in this campus. A total of 48,000 L fed-batch and 6,000 L perfusion bioreactor capacity will be installed, representing the world's largest facility using single-use bi | WuXi Biologics | Manufacturing Investment | Ireland |
| Paragon Medical | 375 | The acquisition of Paragon Medical fits perfectly with our strategic plan and stated goal of expanding our life sciences portfolio. Paragon strengthens our technical abilities, expands our product and finished device offerings, and adds key talent across our organization that will help us continue to drive growth in our end markets. | NN, Inc. | Acquisition | United States |
| Proximagen | 370 | USL2612 is a novel investigational midazolam formulation, which has been specifically designed for intranasal delivery without active inhalation. It has been granted orphan drug designation and fast track designation by the United States Food and Drug Administration (FDA), reflecting the significant unmet need which currently exists for ARS rescue treatment. | UCB | Asset Acquisition | United Kingdom |
| Healthium Medtech (HMPL) | 350 | Through its strong pan-India distribution presence under the Sutures India division, Healthium sells its products across large and corporate hospitals, nursing homes, and government hospitals and institutions, and services over 10,000 hospitals across the country. Backed by the Apax Funds, Healthium plans to further deepen its presence in the Indian market and broaden its portfolio of specialty medtech products. | Apax Partners | Acquisition | India |
| Ionis Pharmaceuticals | 330 | AstraZeneca will be responsible for further development and commercialization of IONIS-AZ6-2.5-LRx. | AstraZeneca | License Agreement | United States |
| Allogene Therapeutics, Inc. | 300 | Pfizer Inc. and Allogene Therapeutics, Inc. today announced that the two companies have entered into an asset contribution agreement for Pfizer’s portfolio of assets related to allogeneic chimeric antigen receptor T cell (CAR T) therapy, an investigational immune cell therapy approach to treating cancer. | Pfizer Inc. | Series A Financing | United States |
| Clovis Oncology, Inc. | 300 | Clovis Oncology intends to use the combined net proceeds of the offerings for general corporate purposes, including sales and marketing expenses associated with Rubraca® (rucaparib) in the United States and, if approved by the European Commission, in Europe, funding of its development programs, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. | | Registered Direct Offering | Canada |
| Mallinckrodt plc | 300 | The debt was issued by Mallinckrodt International Finance SA in 2013 in preparation for the company's spin-off from its former parent | Mallinckrodt International Finance SA | Debt Repayment | United Kingdom |
| nVision Medical Corporation | 275 | Boston Scientific plans to conduct additional clinical research with the nVision device to further establish how the cells it collects from the fallopian tubes can be used to render a diagnosis prior to surgery and help in the decision-making process for women at increased risk for ovarian cancer. | Boston Scientific Corporation | Acquisition | United States |
| Intercept Pharmaceuticals | 250 | Funding the ongoing commercialization of Ocaliva in primary biliary cholangitis and the continued advancement of Intercept’s clinical, research and development programs. | | Registered Direct Offering | United States |
| MorphoSys AG | 239 | In total, MorphoSys expects the gross proceeds of the transaction to amount to USD 239,006,800, comprising the base offering of 8,300,000 ADSs (USD 207,832,000) and, upon closing, the exercised option to purchase 1,245,000 additional ADSs | | Registered Direct Offering | Germany |
| Compugen Inc. | 210 | Compugen will provide an exclusive license to MedImmune for the development of bi-specific and multi-specific antibody products derived from a Compugen pipeline program. MedImmune has the right to create multiple products under this license and will be solely responsible for all research, development and commercial activities under the agreement. | MedImmune (AstraZeneca plc) | License Agreement | Israel |
| Somerset Therapeutics, LLC, Wintac Limited | 190 | Endo is paying approximately $190 million in total for Somerset Therapeutics and Wintac's business. Together, the acquisitions will secure for Endo's Par Sterile injectable business Somerset Therapeutics' commercial and pipeline products as well as Wintac's manufacturing capabilities for those products. | Endo International plc | Acquisition | United States |
| LivaNova PLC | 190 | LivaNova’s portfolio is now concentrated on our areas of strength and leadership: cardiac surgery and neuromodulation. This transaction enables us to concentrate our efforts on developing market-leading businesses in these areas, and will assist us in enhancing LivaNova’s position as an innovative medical device company that improves the lives of patients around the world and creates value for our shareholders. | MicroPort Scientific Corporation | Divestment | United Kingdom |
| Cellectis | 164 | The net proceeds to Cellectis from the offering are approximately $163.7 million, after deducting the estimated expenses related to the offering and the underwriting discounts and commissions payable by Cellectis. In connection with the offering, Cellectis granted the underwriters a 30-day option to purchase up to an additional 846,900 ADSs. | | Registered Direct Offering | France |
| Innovent Biologics, Inc. | 150 | Capital Group Private Markets, a unit of U.S. investment firm Capital Group Companies, has led a US$150 million round in Chinese biotech firm Innovent Biologics, Inc. | Capital Group Private Markets | Series E Financing | China |
| Tocagen Inc. | 147 | Toca 511 & Toca FC is a cancer-selective immunotherapy currently under evaluation in an international Phase 3 trial, called Toca 5, for patients with recurrent high grade glioma (HGG), a type of brain tumor. The product candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) and PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA). | Beijing Apollo Venus Biomedical Technology Limited (ApolloBio Corp.) | License Agreement | United States |
| 10x Genomics | 125 | The proceeds from these financings will fuel the Company’s innovation engine and will allow investment in new strategic opportunities. The funding will also help 10x to continue to expand its global commercial organization, including new offices in Leiden, The Netherlands and Shanghai, PRC, as well as to expand its internal manufacturing capabilities. | Wells Fargo Strategic Capital | Series D Financing | United States |
| Surface Oncology, Inc. | 119.5 | In addition to the shares sold in the public offering, Surface announced the completion of the concurrent sale of an additional 766,666 shares at the initial offering price of $15.00 per share, for gross proceeds of $11.5 million, in a private placement to Novartis Institutes for Biomedical Research, Inc. The sale of these shares was not registered under the Securities Act of 1933, as amended, and the shares are subject to a 180-day lock-up agreement. | Novartis Institutes for Biomedical Research, Inc. | Aggregate Financing | United States |
| BenevolentAI | 115 | BenevolentAI’s current drug development portfolio demonstrates that it can cut early stage drug discovery by four years and potentially deliver efficiencies in the entire drug development process of 60% against pharmaceutical industry averages – significantly disrupting an industry that spends $180bn a year on R&D. | Woodford Investment Management | Financing | United Kingdom |
| Spark Therapeutics | 110 | Under the PRV program, a sponsor who receives FDA approval for a rare pediatric disease drug or biologic may qualify for a voucher to be redeemed at a future time for priority review of a subsequent marketing application for a different product. The PRV was received when LUXTURNATM (voretigene neparvovec-rzyl) was approved by the U.S. Food and Drug Administration (FDA). | Jazz Pharmaceuticals | Priority Review Voucher | United States |
| MacroGenics | 110 | The exercise of the underwriters’ option to purchase additional shares brought the total number of shares of common stock sold by MacroGenics in the offering to 5,175,000 and increased the gross proceeds from the offering (before deducting underwriting discounts and commissions and estimated offering expenses) to approximately $110.0 million. | Leerink Partners | Registered Direct Offering | United States |
| Lasergen, Inc. | 105 | Acquisition affirms Agilent’s strategic intent to grow in the diagnostics space and build a complete routine clinical NGS workflow | Agilent Technologies | Acquisition | United States |
| Livongo Health | 105 | Proceeds from the offering will support rapid market growth, continued investment in data science, deeper integration with clients and partners, and the development of Livongo’s comprehensive consumer platform based on the company’s ‘whole person’ approach. | General Catalyst | Financing | United States |
| Entasis Therapeutics Holdings Inc. | 103.6 | Collaboration will facilitate enrollment of pivotal global Phase 3 trial of ETX2514 in combination with sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii infections. | Zai Lab Limited | License Agreement | United States |
| Constellation Pharmaceuticals | 100 | Proceeds Will Help to Advance the Company’s Cancer Epigenetics Platform and Accelerate Development of Ongoing Therapeutic Programsn | Cormorant Asset Management, Deerfield Management, Fidelity Management and Research Company, Hillhouse Capital, NS Investment, OrbiMed, Sirona Capital, Venrock Healthcare Partners, The Column Group, Third Rock Ventures, Venrock, SROne, University of California Investment Office, Topspin Partners, and Casdin Capital. | Financing | United States |
| Institute of Human Virology | 100 | The work is funded by the U.S. Centers for Disease Control and Prevention (CDC) through the President’s Emergency Plan for AIDS Relief (PEPFAR), in collaboration with the Government of Nigeria and the Global Fund to Fight AIDS, Tuberculosis and Malaria, to conduct the Nigeria AIDS Indicator and Impact Survey (NAIIS). IHV will lead the effort to measure the impact of HIV programs on the epidemic in Nigeria. The results of the survey will guide a strategy for Nigeria’s HIV prevention and treatment | | Survey Project | United States |
| Multilateral Initiative on Malaria Conference, Malaria Summit of the Commonwealth | 100 | Novartis announces a five-year commitment to the fight against malaria in conjunction with the 7th Multilateral Initiative on Malaria Conference and the Malaria Summit of the Commonwealth Heads of Government meeting. Further, the company releases new African research on progress and remaining challenges toward the 2030 malaria elimination targets, together with Elimination 8 and the KEMRI-Wellcome Trust program. | Novartis Group | Research Agreement | United Kingdom |
| Mayne Pharma | 80 | The new facility quadruples Mayne Pharma’s capacity to manufacture oral solid-dose pharmaceuticals in the United States. A key highlight of this expansion is Mayne Pharma’s commercial-scale, solvent-based, fluid-bed processing and film coating — a first for its operations in the United States. With this facility, Mayne Pharma triples itsnfluid-bed processing capacity globally. Metrics Contract Services is now able to offer clients a comprehensive ‘concept to commercialization’ solution under on | | Manufacturing Investment | Australia |
| Undisclosed | 77.7 | The German group has laid the first stone of a 5,700 sq m building at its Lyon Porte-des-Alpes (LPA) site. Known as F2IVE (Formulation and Filling of Inactivated Vaccines Extension), this major project will comprise a three-storey building - including 1,000 sq m of clean room space – mainly for formulating and distributing avian vaccines. | Boehringer Ingelheim | Investment | France |
| Orexigen Therapeutics, Inc. | 75 | Under the terms of the agreement, Orexigen will sell the world-wide rights to Contrave® (naltrexone HCl / bupropion HCl extended release) /Mysimba™ (naltrexone HCl and bupropion HCl prolonged release) and certain other Orexigen assets for $75 million in cash. The deal is subject to higher and better offers. | Nalpropion Pharmaceuticals, Inc. | Asset Purchase Agreement | United States |
| Doctor On Demand | 74 | Doctor On Demand offers immediate access to board-certified physicians, psychiatrists, and licensed psychologists via smartphones, tablets, or desktop computers. | Princeville Global | Series C Financing | United States |
| Humco | 70 | This mutually beneficial merger will allow Humco to strengthen and add value to customers through Fagron’s extensive line of Active Pharmaceutical Ingredients, product portfolio and strong research and development. | Fagron Group BV | Merger Agreement | United States |
| Crescendo Biologics Ltd. | 70 | Crescendo Biologics Ltd (Crescendo) the developer of multi-functional biologics with a focus on novel targeted T-cell engagers, announced today that it has completed a $70 million (€57 million) Series B financing. | Andera Partners | Series B Financing | United Kingdom |
| Beijing Biocytogen Co., Ltd. | 65 | This financing round was led by CMB International Capital and followed by SDIC Venture Capital (Round B leading investor), 3E Bioventures, Cowin Capital and Oriza Seed. Biocytogen will dedicate the funds raised on this round toward market development, technology and product development, construction of new base facilities as well as expanding its talent pool. | CMB International Capital Corporation Ltd | Series C Financing | China |
| Visionsense | 65 | Visionsense develops a minimally invasive stereoscope camera that enables 3D visualization of difficult areas, such as the brain, during surgery. | Medtronic PLC | Acquisition | Israel |
| Eidos Therapeutics | 64 | Funding supports Phase 2 clinical trials of AG10, a potential best-in-class therapy for transthyretin amyloidosis, and ongoing preparation for Phase 3 clinical trials | RA Capital | Series B Financing | United States |
| Synthorx Inc. | 63 | The financing proceeds will be used to advance Synthorin IL-2 into clinical trials in immune-oncology and further progress the company’s cytokine pipeline.n | OrbiMed | Series C Financing | United States |
| C3i Solutions (Merck & Co.) | 60 | C3i’s expertise in the clinical, pharmacovigilance, and pharma sales support domains and the strong partnership will enable HCL’s life sciences customers to become more patient-centric and offer services to IT and business stakeholders | HCL Technologies | Acquisition | United States |
| Corvidia Therapeutics | 60 | Corvidia Therapeutics is nearing completion of a Phase 2 clinical trial for a genetically-defined patient population living with advanced chronic kidney disease. Presently, the Company is scientifically-focused on cardiovascular indications utilizing the study of genetic variations to ultimately deliver precise treatments to specific patients who have an unmet medical need. The Series B funding will be used to progress the lead clinical programs in chronicnkidney disease and beyond as well as a | Venrock Healthcare Capital Partners (VHCP) | Series B Financing | United States |
| Novavax, Inc. | 57.5 | Net proceeds from the offering are to be used for general corporate purposes, including but not limited to working capital, capital expenditures, research and development expenditures related to clinical and preclinical vaccine candidates, clinical trial expenditures, as well as acquisitions and other strategic purposes. | | Registered Direct Offering | United States |
| Cedilla Therapeutics | 56.2 | Cedilla is leveraging a growing understanding of the principles that dictate protein stability and applying those principles to target proteins that drive cancer and other diseases. Cedilla’s integrated product engine includes target-centric and unbiased approaches and is designed to produce small molecule therapeutics that degrade protein targets. Although degradation by small molecules has been observed serendipitously, degradation as a mechanism of action has not been pursued systematically i | Third Rock Ventures | Series A Financing | United States |
| Inovio Pharmaceuticals | 56 | CEPI will fund up to $56,000,000 to support Inovio’s pre-clinical and clinical advancement through Phase 2 of INO-4500, its Lassa fever vaccine, and INO-4700, its MERS vaccine. The shared goal of Inovio and CEPI is for the Lassa and MERS vaccines to be available as soon as possible for emergency use. | Coalition for Epidemic Preparedness Innovations (CEPI) | Partnership | United States |
| REVOLUTION Medicines, Inc. | 56 | The financing was supported by a syndicate of premier life sciences investors led by Nextech Invest, an oncology-focused investment firm, and included participation from Casdin Capital, Schroder Adveq, The Column Group, Third Rock Ventures and additional undisclosed institutional investors. | Nextech Invest | Series B financing | United States |
| Arvinas LLC | 55 | Proceeds from the financing will support the advancement of the Company's two lead programs toward clinical investigation. The two programs, which target the androgen receptor for castration resistant prostate cancer and the estrogen receptor for ER+ positive breast cancer, both nominated orally available clinical candidates in the fourth quarter of 2017. These proceeds will also advance the Company's early stage oncology pipeline, CNS pipeline, and efforts on undruggable targets. | Nextech Invest | Series C Financing | United States |
| Magenta Therapeutics | 52 | Proceeds from the financing will be used to advance Magenta’s integrated portfolio of novel therapeutics, which are designed to address major unmet needs in bone marrow transplantation. This includes Magenta’s targeted bone marrow transplant conditioning programs, stem cell mobilization and stem cell expansion programs. | Casdin Capital | Series C Financing | United States |
| Twist Bioscience | 50 | To use a portion of these funds to invest in the emerging vertical market opportunity presented by storing digital data in DNA as well as forward integration toward drug discovery | | Private Placement | United States |
| Securus Medical Group, Inc. | 50 | Acquisition strengthens electrophysiology cardiac ablation portfolio with thermal monitor | Boston Scientific Corporation | Acquisition | United States |
| Tessa Therapeutics | 50 | Tessa's Virus-Specific T cell (VST) technology is showing compelling results and an excellent safety profile in the treatment of cancer. | Novo Nordisk A/S | Series A Financing | Singapore |
| Tetherex Pharmaceuticals, Inc. | 50 | Proceeds from the financing will be used to conduct a Phase 2 clinical trial evaluating the company's potential, first-in-class P-Selectin Glycoprotein Ligand-1 (PSGL-1) inhibitor candidate, SelK2, in the treatment of venous thromboembolism (VTE) in patients undergoing total knee replacement surgery. | MPM Capital | Series B Financing | United States |
| STEMCELL Technologies | 45 | The five-year, $138 million project will build a new advanced manufacturing facility for biologics in Burnaby, British Columbia. This new facility will make it possible for STEMCELL to manufacture its products at the higher regulatory compliance standard required to support clinical trials in the rapidly evolving sciences of cell therapy, tissue engineering, immunotherapy, gene therapy and regenerative medicine, with the ultimate aim of curing cancer and other serious diseases. | Governments of Canada and British Columbia | Grants & Awards | Canada |
| Virta Health | 45 | The clinically-proven Virta Treatment reverses type 2 diabetes and significantly improves several chronic comorbidities, taking direct aim at these skyrocketing healthcare costs and nearly one-third of the more than $3 trillion in annual U.S. healthcare spend. | Venrock | Series B Financing | United States |
| Inventiva S.A. | 44 | Funds raised will allow Inventiva to advance its portfolio of compounds in the clinic, in particular its lead compound, lanifibranor, through preparatory studies towards a Phase III trial for the treatment of NASH, a growing liver disease that affects more than 30 million people in the United States, and of systemic sclerosis an orphan disease with high unmet medical needs. Funds will also allow Inventiva to advance its second program, odiparcil, a drug candidate for the treatment of multiple fo | Namsen Capital | Capital Increase | France |
| Juniper Pharmaceuticals, Inc. | 44 | The Juniper intravaginal ring technology allows for sustained drug delivery over time periods ranging from weeks to months. Unlike other vaginal rings, the Juniper intravaginal rings release drugs in a solid ethylene vinyl acetate polymer matrix without the need for a membrane or reservoir to contain the active drug or control the release. In addition to its newly acquired platform, Daré has two products currently in clinical development, including its lead candidate OvapreneTM, the non-hormonal | Daré Bioscience | License Agreement | United States |
| Enterprise Therapeutics | 41 | Enterprise Therapeutics is developing muco-regulatory therapies to treat patients with respiratory diseases of high unmet medical need, where mucus obstruction reduces lung function, leading to difficulty in breathing and recurrent lung infections. These novel therapies target the ion channels TMEM16A and ENaC, to increase the hydration and clearance of mucus. Enterprise Therapeutics has also identified novel targets and compounds that reduce mucus production, an approach that complements mucus | Versant Ventures | Series B Financing | United Kingdom |
| Axonics Modulation Technologies, Inc. | 40.1 | Equity Round of $20 million led by Longitude Capital with Silicon Valley Bank Providing a $20 million Credit Facility | Longitude Capital | Equity Financing | United States |
| Genevant Sciences (Arbutus Biopharma) | 37.5 | Genevant aims to advance 5-10 product candidates into the clinic by 2020 across RNAi, mRNA, and gene editing modalities using Arbutus’ LNP and ligand conjugate platforms | Roivant Sciences, Arbutus Biopharma | Seed Capital | United States, Switzerland |
| Rallybio, LLC | 37 | Rallybio was co-founded in January 2018 by Martin Mackay, PhD, Stephen Uden MD, and Jeffrey Fryer, CPA, recognized leaders from the biopharma industry. The Company will develop innovative drug candidates against mechanisms that have strong biological rationales. Rallybio’s focus is on antibodies, small molecules and engineered proteins. | 5AM Ventures | Series A Financing | United States |
| Intec Pharma | 35.4 | Intec Pharma intends to use the net proceeds from this offering to fund its Phase III clinical trial for Accordion Pill Carbidopa/Levodopa, the company's leading product candidate for the indication of treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, to advance its pre-commercial activities and for working capital and other general corporate purposes. | Oppenheimer & Co. Inc. | Registered Direct Offering | Israel |
| Attenua, Inc. | 35 | Attenua, Inc., a clinical-stage biopharmaceutical company focused on developing novel medicines to treat cough, today announced the completion of a $35 million Series A financing. The financing was led by Omega Funds with participation from a syndicate of leading international healthcare investors including Abingworth, OrbiMed and Redmile Group LLC. | Omega Funds | Series A Financing | United States |
| Tmunity Therapeutics, Inc. | 35 | The proceeds from the Series A will be used to advance and expand the business and operational structure of Tmunity to support the rapid translation, development and manufacture of its portfolio of novel T cell based immunotherapies, first for the treatment of cancer. Kleiner Perkins and affiliates join existing Tmunity investors Ping An Ventures, Parker Institute for Cancer Immunotherapy, Gilead Sciences, Inc., Be The Match BioTherapies, University of Pennsylvania and Lilly Asia Ventures. | Kleiner Perkins | Series A Financing | United States |
| CMAB Biopharma Inc. | 34 | Upgrading CMAB's 2,000L Good Manufacturing Practices (GMP) facilities and will also enable the company to provide 50L/200L/500L/1,000L/2,000L bioreactor scale GMP manufacturing services. | CD Capital, C-Bridge Capital, Cormorant, Qianhai FoF Fund and Tigermed | Series B Financing | China |
| Elekta | 34 | Elekta MR-linac is the only radiation therapy delivery system that integrates an advanced linear accelerator with cutting-edge, high-field (1.5 Tesla) magnetic resonance imaging without compromising either system. Elekta MR-linac has extraordinary potential for ushering in a new paradigm of cancer care. | Proton Partners International Ltd | Asset Acquisition | Sweden |
| LimFlow SA | 33.5 | Proceeds from the Series C financing will fund the company’s major strategic initiatives through the second half of 2020, including completion of a U.S. pivotal trial for the LimFlow Percutaneous Deep Vein Arterialization System (pDVA), which will be submitted to the FDA as part of the approval process, and execution of its international commercialization strategy. | Sofinnova Partners | Series C Financing | France |
| EryDel SpA | 32 | Funds will be used to accelerate the company’s international development and complete the registrational Phase III clinical trial of its lead product EryDex. | Sofinnova Partners | Financing | Italy |
| Element Genomics, Inc. | 30 | At the core of the Element Genomics platform is a suite of technologies to improve understanding of genome structure and function such as CRISPR editing technologies used for genomic and epigenomic regulatory region analysis and modulation, underpinned and enabled with advanced informatics capabilities, and driven by a strong scientific team. | UCB | Acquisition | United States |
| BRF Hospitals | 30 | University Health System provides advanced healthcare for patients in Shreveport, Monroe and surrounding areas. Operating the region’s only Level 1 Trauma Center, UHS combines quality care with research-based methods to provide leading service and 3,000 jobs in the community. UHS is one of just six hospitals in the nation affiliated with St. Jude Children’s Research Hospital and home to state-designated Centers of Excellence, including the Feist-Weiller Cancer Center. | White Oak Healthcare Finance, LLC | Senior Credit Facility | United States |
| Medical Microinstruments | 24.5 | Medical Microinstruments is pioneering a disruptive advance in this surgical space by coupling the dexterity of robotically controlled wrist articulation with 5x to 40x motion scaling to match optical magnification. | Andera Partners | Series A Financing | Italy |
| Peptron Inc. | 24 | Peptron also raised USD$24 million for Phase 2 clinical trial of SR-exenatide in Parkinson's disease and operations of new manufacturing facility, which opens April 26 | National Institutes of Health (NIH) | Expansion of License Agreement | South Korea |
| BerGenBio ASA | 24 | BerGenBio intends to use the net proceeds of the Private Placement to fund the ongoing clinical development of pipeline candidates, strengthen working capital and general corporate purposes. | | Private Placement | Norway |
| Macrolide Pharmaceuticals | 20 | The new funding from both the financing and previously announced CARB-X award will accelerate development of the company’s novel, IV and orally-available macrolide antibiotics to address serious infections, including work to support filing an Investigational New Drug (IND) application for its lead program that addresses a significant unmet clinical need that exists for antibiotics to treat infections caused by resistant Gram-negative pathogens. The company is broadly pursuing novel macrolide ant | GlaxoSmithKline (SR One) | Investor Financing | United States |
| Intact Vascular, Inc. | 20 | The Tack Endovascular System is a new solution for precision dissection repair following balloon angioplasty with a first-of-its-kind implant that is designed to help maintain vessel integrity and enhance blood flow to promote healing, improve outcomes and preserve limbs. Unrepaired dissections — which are frequent following balloon angioplasty — increase the probability of acute arterial occlusion and may continue narrowing the artery, which leads to lower long-term patency rates. The Tack Endo | New Enterprise Associates | Series C Financing | United States |
| Pharnext SA | 19.14 | The proceeds from the private placement will provide the Company with additional resources to fund its strategy and continue its growth in the perspective of the forthcoming results of the Phase 3 trial of its most advanced PLEODRUG™, PXT3003 in the treatment of Charcot-Marie-Tooth disease type 1A. | | Private Placement | France |
| TFF Pharmaceuticals, Inc., | 14 | In early testing the Company's Thin Film Freezing (TFF) proprietary platform significantly improved the solubility of drugs that have poor water solubility. The TFF Pharmaceuticals platform does not require a proprietary device, excipient or delivery molecule to obtain deep lung delivery of small molecules, biologics, or uniform combo drugs of small molecules and/or biologics. | Liquid Venture Partners, National Securities Corporation | Series A Financing | United States |
| Achaogen, Inc. | 12 | The collaboration will focus on the development of a next-generation broad-spectrum aminoglycoside antibiotic capable of overcoming clinically-relevant resistance mechanisms and potentially treating highly-resistant gram-negative pathogens such as the Enterobacteriaceae family, Acinetobacter baumannii, and Pseudomonas aeruginosa. | Combating Antibiotic Resistant Bacteria Accelerator (CARB-X) | Grants & Awards | United States |
| Undisclosed Research Associations | 11.8 | MRA’s 2018 grants are made possible through the significant contributions of individuals, families, institutions and corporate allies. Donors and partners providing financial support for 75% or more of an award are listed below within the award naming. | Melanoma Research Alliance (MRA) | Strategic Alliance | United States |
| Promethera Biosciences SA | 11.5 | The proceeds will be used to accelerate the progression of Promethera’s clinical pipeline and to continue expanding the company’s research and development activities in addressing liver disease indications with significant unmet medical need such as acute-on-chronic liver failure (ACLF), nonalcoholic steatohepatits (NASH) and fibrosis. | Shibuya Corporation, Shinsei Corporate Investment | Bond Offering | Belgium |
| Grifols | 11 | Under the agreement, Grifols will finance current and future research lines to advance the search for new treatments for HIV/AIDS and associated diseases, such as infectious, oncological, neurodegenerative and age-related conditions. Enable the study of the human microbiome and emerging infectious diseases, and leverage its accumulated knowledge on HIV/AIDS and resultant immune disorder. | IrsiCaixa | Collaboration | Spain |
| Syna Therapeutics | 11 | The pharmaceutical company Reig Jofre strengthens its commitment to open innovation and the development of injectable and freeze-dried products with the creation of the joint venture Syna Therapeutics, for the development of biopharmaceutical products in the field of biosimilar products and innovative molecules for a world market of around 1,000 million euros. | Laboratoris Reig I Jofre, LeanBio S.L. | Joint Venture | Spain |
| Groninger & Co. GmBH | 11 | Sharp – part of UDG Healthcare plc, a global leader in contract packaging and clinical supply services, has announced an investment of $11 million to increase its global cold storage and syringe assembly capacity in response to market demand. | Sharp (UDG Healthcare plc) | Investment | Germany |
| NuProbe | 11 | In pre-clinical trials, NuProbe’s technology improved qPCR and NGS mutation detection sensitivity by 10-100 fold with limit of detection down to 0.01 percent, and showed a multiplexing capability of 10-100 reactions for detecting hundreds of mutations in the same test tube. | Sequoia China | Series A Financing | United States |
| RubrYc Therapeutics | 10 | RubrYc is focused on improving drug discovery through proprietary insights into critical interactions at the drug/target interface. Using diverse chemical libraries developed and supplied by HealthTell, Inc., RubrYc is training algorithms that inform improved decision-making throughout drug discovery. The company will be collaborating with biotechnology companies in early drug discovery and developing its own molecules. | Paladin Capital Group | Equity Financing | United States |
| Brainomix | 9.8 | Boehringer Ingelheim Venture Fund (BIVF), the corporate venture fund of the global pharmaceutical company Boehringer Ingelheim, a driving force in the field of stroke, joined the round, which was led by university investment veterans Parkwalk Advisors. Existing investors Chimera Partners and Oxford University Innovation Fund also participated. | Boehringer Ingelheim | Investment | United Kingdom |
| Minnesota Cancer Clinical Trials Network (MNCCTN), Minnesota's Discovery, Research and InnoVation Economy (MnDRIVE) | 8 | Led by the Masonic Cancer Center, University of Minnesota, the goal of the MNCCTN is to improve prevention, treatment and survivorship for all Minnesotans through greater access to cancer clinical trials. These trials will originate from Minnesota’s two NCI-Designated Comprehensive Cancer Centers, the Masonic Cancer Center and Mayo Clinic Cancer Center, along with the Hormel Institute in Austin. | Masonic Cancer Center, University of Minnesota | Partnership | United States |
| Undisclosed | 7.36 | ExxonMobil’s malaria initiative helps to advance progress against the disease by working with nonprofit partners to build health system capacity, further malaria education, advance research and development, improve access to tools for prevention and treatment and support rising global health leaders. | ExxonMobil | Grants & Awards | United States |
| X-Biotix Therapeutics, Inc. | 7 | Proceeds of the financing will enable X-Biotix to advance its pipeline of novel antibiotic candidates targeting a wide range of biological targets in essential pathways of Gram-negative bacterial cells. | Harvard Medical School | Series A Financing | United States |
| Nursing Home Facility | 6.4 | The parties will negotiate in good faith toward definitive agreements regarding the project. WHL would lease the land and be the developer of the project and would own the buildings on the site. WHL would have full control of the design and supervision of the construction of the project, as well as daily operations and management of the project. | Union Bridge Holdings | Binding Heads of Agreement for Cooperative Venture | Thailand |
| ReShape Lifesciences | 6 | If the requisite stockholder approval is obtained, and if the warrants are exercised in full, ReShape Lifesciences would receive an additional $26.25 million in gross proceeds based on the initial warrant exercise price of $0.75 per share. ReShape Lifesciences intends to use the net proceeds from the registered direct offering to continue its commercialization efforts, for clinical and product development activities, and for other working capital and general corporate purposes. | Ladenburg Thalmann & Co. Inc., Euro Pacific Capital Inc. | Securities Purchase Agreement | United States |
| NovellusDx | 6 | "The additional funds will allow us to accelerate the execution of our strategy, move into commercialization and enable us to meet the need for functional oncology worldwide. This funding will also support continuing development and enhancement of NovellusDx’s technology using our excellent R&D team in Jerusalem”, said Haim Gil-Ad, CEO of NovellusDx. | Helsinn Investment Fund | Equity Financing | Israel |
| Takeda Pharmaceutical Company Limited, DNDi | 5.6 | The project has been selected for funding by the Global Health Innovative Technology Fund ("GHIT"). GHIT is an international public private partnership fund that facilitates global R&D partnerships for the discovery and development of new health technologies needed in developing countries. The Takeda-DNDi partnership will receive a sum of approximately 600 million yen from GHIT in support of its studies. | Global Health Innovative Technology Fund (GHIT) | Clinical Collaboration | Japan |
| DNA Script | 5.5 | New grants will accelerate DNA Script’s commercialization of its novel high speed, high efficiency, free-of-harsh-chemicals DNA synthesis technology | Horizon 2020 European Innovation Council Program, Aide au développement de l’innovation and Concours Mondial d’innovation programs of Bpifrance | Non-dilutive Financing | France |
| Takeda Pharmaceutical Company Limited | 5 | To develop and commercialize T-3525770 (now RM-853). RM-853 is a potent, orally available ghrelin o-acyltransferase (GOAT) inhibitor currently in preclinical development for Prader-Willi Syndrome (PWS) | Rhythm Pharmaceuticals | License Agreement | Japan |
| Cincinnati Children's Center for Stem Cell and Organoid Medicine (CuSTOM) | 5 | Transformational investment boosts human organ generation research | Farmer Family Foundation | Donation | United States |
| Diaceutics | 5 | Financing will enable Diaceutics to accelerate product development, provide more support to pharmaceutical clients and improve patient testingn | Whiterock Capital Partners LLP | Mezzanine Financing | United States |
| RXi Pharmaceuticals | 4.9 | The net proceeds of the offering are estimated to be approximately $4.1 million, after deducting placement agent fees and estimated offering expenses. RXi plans to use the net proceeds to fund the preclinical and clinical development of its immuno-oncology program, for other research and development activities and for general working capital needs. | H.C. Wainwright & Co., LLC | Registered Direct Offering | United States |
| Shenyang Shenhe Yixi Home Care Service Center | 4.9 | Shenyang Yixi operates 12 community elderly day-care centers (elderly day-care centers or activity centers) and a district home-care service center (a home-based elderly care center to provide service to the elderly at home) in, which are owned by the government. | Phoenix Creation Global Limited, (Union Bridge Holdings) | Letter of Intent | Hong Kong |
| Moberg Pharma | 4.25 | Balmex contains zinc oxide, the #1 doctor recommended ingredient for fighting diaper rash, plus a natural ingredient shown to help neutralize digestive enzymes that are known to irritate the skin. Balmex creates a highly effective, long lasting barrier that helps keep wetness away from the skin. Balmex’s protective barrier also reduces friction on the skin caused by contact with the diaper as well as chafing from skin-on-skin contact. | Randob Labs | Divestment | Sweden |
| Technology Touching Life | 4 | Five research networks, awarded £3 million through a joint technology initiative, will harness new and emerging developments from the engineering and physical sciences to advance life sciences discovery research. | Medical Research Council (MRC) | Grants & Awards | United Kingdom |
| Zucara Therapeutics | 3.9 | As part of the agreement, Helmsley will provide the funding to support preclinical advancement of Zucara’s lead drug candidate. The partnership is structured as a program-related investment (PRI) in the form of a loan to Zucara. | Helmsley Charitable Trust | Non-dilutive Financing | Canada |
| Abbott India | 3.8 | Corona Remedies, the Ahmedabad-headquartered mid-sized pharmaceutical firm, has acquired two diabetes and hyperthyroidism brands, Obimet and Thyrocab, comprising 14 product line extensions, from multinational drug major Abbott India for an undisclosed sum. | Corona Remedies | Brand Acquisition | India |
| Apricus Biosciences | 3.55 | Total gross proceeds from the offering were approximately $3.55 million, before deducting the placement agent’s fees and other estimated offering expenses payable by Apricus. Apricus intends to use the net proceeds from the offering for working capital and general corporate purposes. | | Registered Direct Offering | United States |
| CorWave | 3.5 | The aim of the Worldwide Innovation Challenge is to foster talent and pave the way for the emergence of France’s future economic champions. The challenge is financed by the Invest for the Future Program (PIA) and managed by Bpifrance. With this new financing, CorWave will be able to step up the pace of development of NovaPulse, a new mini-invasive cardiac support pump, and thereby improve the care of older patients suffering from chronic heart failure, one of the leading causes of death worldwid | France’s Concours Mondial d'Innovation | Financing | France |
| Trevena, Inc. | 3 | Pharmbio Korea granted a license to develop, manufacture, and commercialize oliceridine in South Korea. Trevena to receive upfront and milestone payments and royalties, Oliceridine is currently under review by the U.S. Food and Drug Administration for potential approval in the United States for the management of moderate-to-severe acute pain. | Pharmbio Korea | License Agreement | United States |
| IDT Australia, Ltd. | 2.7 | Today’s acquisition gives ANI full control of the re-commercialization program and the vast majority of the economics for these products. | ANI Pharmaceuticals, Inc. | Recommercialization Agreement | Australia |
| FIMECS, Inc. | 2.3 | The company received compound assets including first-in-class E3 ligase binders and novel pseudokinase targeting binders, which enable the acceleration of protein degradation therapeutics to ‘undruggable’ targets — a critical area of cancer research requiring new innovation. | Takeda Pharmaceutical Co., Ltd. | License Agreement | Japan |
| 4P Therapeutics Inc. | 2.3 | 4P Therapeutics will now become the Pharmaceutical and Development arm of Nutriband Inc. with a specific focus on Transdermal and Topical Technologies, prescription drugs and clinical development. | Nutriband Inc. | Acquisition | Canada |
| Daré Bioscience | 2.14 | The award will be applied to important clinical development efforts supporting Daré’s lead product candidate Ovaprene™, a non-hormonal, non-daily intravaginal ring being studied for pregnancy prevention. Ovaprene is a clinical stage, non-hormonal contraceptive ring intended to provide protection over multiple weeks of use, requires no intervention at the time of intercourse, and fills a void in today’s contraception method mix. | National Institute of Child Health and Human Development (NICHD) | Grants & Awards | United States |
| Alavida Health | 2 | Alavida Health is a science-based treatment program that combines non-addictive medication, behavioural therapy and technology to help people decrease or stop their consumption of alcohol. Alavida's revolutionary treatment program boasts a 75% success rate and has treated more than 230 clients since 2016. Upon completion of the program, 91% of clients have reduced their drinking, with 75% reducing their alcohol consumption by more than 50%. | Nimbus Synergies Inc. | Financing | Canada |
| Annabis Medical | 1.95 | By combining Canopy Growth's extensive global experience and network with the strong national position of Annabis Medical, Canopy is proud to bring its renowned Spectrum Cannabis brand to another European market. | Canopy Growth Corporation | Acquisition | Czech Republic |
| BioServe Biotechnologies (Cancer Genetics, Inc.) | 1.9 | Under the terms of the definitive agreement, Cancer Genetics received an upfront payment of $1.6 million in cash from REPROCELL. The remaining balance will be payable approximately 6 months from closing and is subject to BioServe’s revenues for a four month period post-closing being equivalent to the same four month period in 2017. | Reprocell | Divestment | United States |
| Dr Borko Amulic (University of Bristol) | 1.63 | University of Bristol researcher Dr Borko Amulic has been awarded the Career Development Award by the Medical Research Council (MRC), worth £1.2 million. The money will be put towards his research into the ability of neutrophil immune cells to fight infections in the post-antibiotic age. | Medical Research Council (MRC) | Grants & Awards | United Kingdom |
| ADC Biotechnology Ltd | 1.56 | ADC Bio announced last month that it is in the process of developing and internally validating its new upstream bioconjugation approach. The highly disruptive method, which leverages the company’s patented Lock-Release technology, would save several months of manufacturing time and up to 25% of overall manufacturing costs. | Downing LLP (Downing FOUR VCT Healthcare) | Investment | United Kingdom |
| Guided Therapeutics, Inc. | 1.1 | In return for the license and manufacturing rights for Cervical Guides in Turkey, the agreement calls for GTHP to receive fees totaling $1,100,000 in 2018, with the first payment due by April 15. In addition, according to the contract, ITEM will pay GTHP a royalty for each Cervical Guide made and sold exclusively in Turkey and ITEM will be obligated to purchase 540 LuViva Advanced Cervical Scans and produce 3,450,000 Cervical Guides for the Turkish market over the next twelve years. | ITEM Medical Technologies Group | License Agreement | United States |
| Aclaris Therapeutics, Inc. | 1 | A-101 40% is a proprietary, high-concentration hydrogen peroxide-based topical solution designed for in-office application by a healthcare provider. It is a targeted treatment applied directly to the raised SK using a pen-like applicator. The most commonly used approaches for SKs are surgical procedures such as cryosurgery, which can cause discomfort, cosmetic imperfections, and require wound management. | Cipher Pharmaceuticals | License Agreement | United States |
| Susan G. Komen | 1 | The funding will continue Komen’s targeted community outreach initiatives through the Conversations with Komen program and enable the organization to open a new satellite office in Milwaukee’s Amani neighborhood. | Kohl’s | Donation | United States |
| ORLink | 1 | ORLink saves hospitals time and money while improving communication and workflows for surgical teams | SAYJ Global Partners | Early Stage Capital | United States |
| Sotera Medical Corp. | 1 | Catheter ablation is a minimally invasive treatment option for patients with AF that can relieve symptoms and improve quality of life. Overall, it is a successful treatment option, but like all procedures, it does carry some risks. One such risk is damage to the esophagus, which, while rare, can become a life-threatening complication. | JumpStart Inc. | Seed Capital | United States |
| Indee Labs | 0.751 | The project will see Indee Labs make a new generation of medicine, known as gene therapy, accessible to the masses. The impact of gene therapies will be similar to that of antibiotics seen during the last century - it will offer cures for most cancer sufferers with minimal side effects. | BioMedTech Horizons Program (Australian Govt.) | Grants & Awards | Australia |
| ModiQuest Research BV | 0.588 | Anticipated accretive annualized revenues of between C$3.5M to C$4.5M for fiscal 2019. Anticipated accretive annualized EBITDA of between C$750,000 to C$850,000 for fiscal 2019. European operations now account for approximately 66% of corporate revenues. Creates single source provider of services across the full antibody discovery value chain, such as an increased variety of therapeutically-focused methods of immunization and antigen design, including several, highly effective methods of genetic | Immunoprecise Antibodies Ltd. | Acquisition | The Netherlands |
| Synpromics Ltd., Lonza Pharma & Biotech | 0.323 | Synpromics has employed its proprietary technology to develop new synthetic inducible/repressible cell-systems that are driven by non-toxic physiological or chemical stimulus, making them ideal for improving productivity and minimising costs during bioproduction. | Innovate UK | Grants & Awards | United Kingdom |
| ViaDerma, Inc. | 0.25 | According to the terms of the agreement, Vage will pay a 50% deposit to ViaDerma upon completion of the registration of Vitastem with the National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria’s equivalent to the FDA. The registration process should be completed within 30 days. The balance of the order will be paid to ViaDerma upon delivery of the product in about 8-10 weeks. | Vage Nigeria Ltd. | Initial Sales Agreement | United States |
| University of Cincinnati, Emory University & University of Chicago | 0.15 | Relypsa will fund the grant awards of up to $50,000 each for one academic year. Relypsa’s grants will fund research in areas vital to improving the care of patients with kidney and heart diseases, including: 1) Defining with greater accuracy the frequency of hyperkalemia in solid organ transplant recipients and correlating their hyperkalemia episodes to clinical episodes; 2) Exploring the influence of potassium and urea levels on fibrosis in animal models of renal dysfunction; and 3) Following p | Relypsa, Inc. (Vifor Pharma Group) | Grants & Awards | United States |
| Undisclosed Research Team of Doctors | 0.05 | As with other adverse childhood experiences (ACEs), alienation is a major risk factor for severe psychological, emotional, and physical harm in adult life and, without prompt and proper intervention, the damage can be permanent. Unfortunately, even for mental health professionals, it is sometimes difficult or challenging to determine the reasons for a child’s rejection of a parent. The purpose of the study would be to identify signs and symptoms in a child that might help professionals to distin | Steel Partners Foundation | Grants & Awards | Canada |
| Verily Life Sciences | Undisclosed | Verily to Deploy Its Immunoscape™ Platform to Generate Insights from Gilead Clinical Trials. Through the collaboration, Gilead will provide clinical data and thousands of immune cell samples from participants before, during and after administration of novel drugs in the company’s ongoing Phase 2 and Phase 3 clinical studies. | Gilead Sciences, Inc. | R&D Collaboration | United States |
| GSK Consumer Healthcare | Undisclosed | Acquistion of consumer healthcare manufacturing unit at Aiken, South Carolina (USA). | Avara Pharmaceutical Services | Acquisition | United States |
| CT Atlantic AG | Undisclosed | XBiotech will use its proprietary manufacturing technology to advance the development of the True HumanTM anti-NY-ESO-1 monoclonal antibody, 12D7 | XBiotech USA, Inc. | License Agreement | Switzerland |
| Scandicure AB | Undisclosed | Servier will continue research started by Scandicure and advance Scandicure’s novel compounds through preclinical development using Servier’s drug discovery capabilities and knowledge of the disease areas. | Laboratoires Servier | Research Agreement | Sweden |
| Veredus Laboratories | Undisclosed | Veredus' Lab-on-Chip technology platform and products have been established as market leaders in the global bio-surveillance market. | Sekisui Chemical Co., Ltd. | Acquisition | Singapore |
| Terns Pharmaceuticals | Undisclosed | The agreement includes a clinical stage farnesoid X receptor (FXR) agonist, TERN-101, a semicarbazide-sensitive amine oxidase (SSAO) inhibitor, TERN-201, which is nearing IND submission, and a preclinical candidate that inhibits an undisclosed, well-validated NASH target. Terns Pharmaceuticals plans to focus initial development activities on regulatory approval in China and explore clinical development in additional global markets. | Eli Lilly | License Agreement | United States |
| Iontas Limited | Undisclosed | The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study. IONTAS will utilise its proprietary antibody discovery technology to help IGEM identify novel IgE antibodies against two targets. | IGEM Therapeutics | R&D Collaboration | United Kingdom |
| DarwinHealth | Undisclosed | DarwinHealth’s proprietary database and technology were created to identify critical mechanisms linked to tumor dependencies and maintenance beyond genetic mutations, and include information on Master Regulators of specific tumor subtypes, as well as direct upstream modulators (both necessary for cancer cell maintenance) across more than 35 tumor and 90 tumor subtypes. | Daiichi Sankyo Company, Limited | R&D Collaboration | United States |
| Inception Neuroscience Program (Pipeline Therapeutics) | Undisclosed | The acquisition is the culmination of a June 2014 alliance between Inception and Roche to discover and develop novel small molecules that promote remyelination of nerve fibers damaged during the progression of multiple sclerosis. | Roche Holding AG, Versant Ventures | Acquisition | United States |
| Dunn Industries, Inc. | Undisclosed | Dunn has expertise in a wide range of thermoplastic materials and offers both standard and custom-engineered tubing solutions. Its product line is also a complementary addition to the microextrusion tubing manufactured by Tekni-Plex’s Natvar business unit. Going forward, it will be known as Dunn Industries, a Tekni-Plex business, with Dunn’s former president Duane Dunn as its general manager. | Tekni-Plex, Inc. | Acquisition | United States |
| Rebiotix Inc. | Undisclosed | The most advanced investigational microbiome treatment from Rebiotix is RBX2660, a non-antibiotic treatment currently in Phase 3 development for the prevention of recurrent CDI. RBX2660 has the potential to be the first human microbiome product approved anywhere in the world. In the US, RBX2660 has received FDA Fast Track, Breakthrough Therapy and Orphan Drug Designations, which means the FDA considers it eligible for Expedited Review, once the submission has been made. | Ferring Pharmaceuticals (Ferring Holding Inc.) | Acquisition | United States |
| The University of Bath | Undisclosed | Sapience will have exclusive rights to the development and commercialization of any novel compounds arising from this research. For molecules developed under the agreement, University of Bath will receive milestone payments associated with clinical development and a royalty on future commercial sales. The agreement also provides Sapience with the right to build, own, operate and partner the discovery platform. | Sapience Therapeutics, Inc. | Drug Discovery Pact | United Kingdom |
| Samsung Bioepis Co., Ltd. | Undisclosed | SB5 has been granted marketing authorization by the European Commission (EC) as IMRALDI®, and will be commercialized in Europe by Biogen. In the US, SB5 has not yet received regulatory approval. | AbbVie Inc. | License Agreement | Korea |
| Ranomics | Undisclosed | VariantFind™ technology is a key component of Ranomics's functional genomics platform, and offers unprecedented scalability and flexibility in building DNA variant libraries. The VariantFindTM technology is used by partners to find meaningful variants in their research programs that will propel discovery and make better products. | Science Exchange | Collaboration | Canada |
| OptiGen, LLC | Undisclosed | Through this evolution, Optigen's clients are believed to benefit from access to an expanded array of multiple tests—both for inherited diseases of particular interest to their breed, as well as to tests for physical traits such as coat color and body size that have not previously been offered by OptiGen. | Mars Petcare | Acquisition | United States |
| Mapi Pharma Ltd. | Undisclosed | The two companies will partner on the development and commercialization of GA Depot, a long-acting Glatiramer Acetate product. Mylan is acquiring global marketing rights to the product - GA Depot. | Mylan N.V. | Partnership | Israel |
| Sleep.ai | Undisclosed | Sleep.ai created an app and wearable for detecting if a user is snoring and/or grinding their teeth, known as bruxism, and helps dentists monitor patients after they've begun dental treatment for either condition. | SleepScore Labs | Acquisition | United States |
| Zealand Pharma | Undisclosed | Zealand has entered a collaboration agreement with Roche Diabetes Care to use its Accu-Chek® Combo pump system in the Phase 3 trials with dasiglucagon for treatment of congenital hyperinsulinism (CHI). Dasiglucagon is a potential first-in-class glucagon analog, currently in plase 3 testing for delivery through infusion via the Accu-Chek® Combo pump system. | Roche Diabetes Care | Clinical Collaboration | Denmark |
| Molecular Partners | Undisclosed | MP0250 offers the possibility of targeting two main tumor escape pathways by blocking both hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) simultaneously while continued treatment with osimertinib suppresses EGFR-mutated NSCLC tumor cells. | AstraZeneca | Collaboration | Switzerland |
| Veracyte, Inc. | Undisclosed | Through the new agreement, Veracyte will use its Afirma Xpression Atlas platform to provide Loxo Oncology with information regarding thyroid cancers with TRK fusions and RET alterations, for use in developing its targeted cancer therapies. | Loxo Oncology | Collaboration | United States |
| Livongo Health | Undisclosed | Cambia and Livongo will collaborate to personalize health care for people who have ongoing health needs in simple, meaningful and tangible ways. Initially, the companies will work together to make Livongo’s category-leading Livongo for Diabetes solution available to Regence Blue Cross and Blue Shield in Idaho, Oregon, Utah, and Washington. The companies will then expand their partnership to co-develop solutions that personalize care for conditions such as hypertension and integrated behavioral h | Echo Health Ventures LLC, Cambia Health Solutions | Partnership | United States |
| Analytica Laser | Undisclosed | Acquisition adds real-world effectiveness prediction and value assessment to Certara’s model-informed drug development and regulatory science decision-making portfolio | Certara | Acquisition | United Kingdom |
| NxGen Brands | Undisclosed | Nutra Pharma is partnering with NxGen Brands, LLC to market and distribute their Over-the-Counter (OTC) pain reliever, Nyloxin® through all of their distribution channels | Nutra Pharma Corporation | Acquisition | United States |
| Australasian Medical & Scientific Ltd (AMSL), New Zealand Medical & Scientific Ltd (NZMS) | Undisclosed | Under the terms of the arrangements, the diabetes divisions of AMSL and NZMS will perform all sales, marketing, and customer training and support for Tandem’s products in the regions. Timing for availability of Tandem products in Australia and New Zealand has not yet been announced. | Tandem Diabetes Care, Inc. | Distribution Agreement | Australia |
| RetroFit | Undisclosed | With the acquisition Livongo adds to its client base innovative health plans and Fortune 1000 employers across a variety of industries. The company also gains a proven, evidence-based, Diabetes Prevention Program, enhances its data science capabilities, and boosts expertise in holistic weight management, including nutrition, exercise and mindset. | Livongo Health | Acquisition | United States |
| GlaxoSmithKline | Undisclosed | GSK takes 19.9% equity stake in Orchard and seat on board | Orchard Therapeutics | Equity Financing | United Kingdom |
| Head and Neck Cancer Alliance | Undisclosed | As part of this joint effort, HNCA will be able to share valuable content through CURE® magazine, where audience will have access to unprecedented content including latest research, interviews and articles that can help oncologists better serve their patients. The SAP Program is designed to facilitate an open exchange of information among trusted peers, the goal of which is to improve patient care. | CURE Media Group | Strategic Alliance | United States |
| Kymera Therapeutics | Undisclosed | Collaboration to Accelerate the Discovery of Protein Degrading Therapeutics. Using a small molecule-mediated knockdown strategy, Kymera rationally designs and develops heterobifunctional molecules that recruit disease-causing proteins to E3 ubiquitin ligases, resulting in the target protein’s ubiquitination and degradation, and the ultimate resolution of cellular dysregulation. | GlaxoSmithKline | Collaboration | United States |
| Miltenyi Biotec GmbH | Undisclosed | Utilising the state-of-the-art, automated cell processing platform CliniMACS Prodigy®, Autolus has established a GMP production process for its programmed T cell therapies designed to address the challenges of commercial-scale manufacturing. | Autolus Limited | Supply Agreement | Germany |
| InSysBio LLC | Undisclosed | The companies together have constructed a complex asthma model which facilitated the investigation of novel medicines and combination therapy scenarios. GSK has chosen InSysBio as a partner to implement a further expansion of the existing model. This will include new targets and clinical trial data to be able simulate more asthma treatment scenarios. | GlaxoSmithKline | Collaboration | Russia |
| PierianDx | Undisclosed | PierianDx will partner with TriCore to bring to market new Next Generation Sequencing (NGS) assays, streamline the genomic data management process, customize reporting, and optimize the variant review and sign-out process. | TriCore Reference Laboratories | Partnership | United States |
| PierianDx | Undisclosed | Through a combination of a highly curated uniquitous knowledgebase, cloud-based software, and clinical lab enablement services, PierianDx simplifies the process of translating complex genomic data into patient-specific diagnosis and treatments. PierianDx’s software platform, the Clinical Genomics WorkSpace (CGW), streamlines accurate analysis, interpretation, and reporting for clinical labs seeking to expand NGS testing and personalized medicine. | RTI International | Strategic Alliance | United States |
| Brazos Biomedical, LLC | Undisclosed | BRAZOS has a proprietary device (AURACIS™) in pre-clinical development to treat headache pain using transcutaneous electrical nerve stimulation (TENS) technology. | American Diversified Holdings Corporation | Acquisition | United States |
| Integrated Wellness Solutions (IWS) | Undisclosed | The IWS acquisition comes as part of DHS Group’s expansion of their wellbeing program; a program that falls under the HealthSpective Engage platform which includes: fitness tracking and wearables, mental, financial and personal health modules. Engage is part of the broader HealthSpective platform, which features three additional modules addressing answers to the full-spectrum of health benefit management needs (benefit program design, health plan enrollment and operation, population health data | Dynamic Health Strategies, LLC (DHS Group) | Acquisition | United States |
| Wave Life Sciences Ltd. | Undisclosed | Under the collaboration, the companies will analyze and test oligonucleotides against potential therapeutic targets within multiple genes implicated in neuromuscular disorders. The analysis will use Deep Genomics’ machine learning platform to identify cause and effect relationships specific to neuromuscular-related targets that involve splicing regulation. | Deep Genomics Inc. | Collaboration | Singapore |
| Ortho Clinical Diagnostics | Undisclosed | The agreement is part of Ortho's ongoing MicroTip Partnership Assays program, through which Ortho collaborates with other diagnostics companies to validate and deliver a broad range of assays to the hospitals, hospital networks and labs who use Ortho's VITROS® 4600 Chemistry System and VITROS® 5600 Integrated System. | Thermo Fisher Scientific | Distribution and Co-promotion Agreement | United Kingdom |
| Nektar Therapeutics | Undisclosed | Nektar and Takeda will each maintain global commercial rights to their respective investigational medicines. Nektar and Takeda will split the costs related to the clinical trial and each company will contribute their respective compounds to the clinical collaboration. | Takeda Pharmaceutical Co., Ltd. | Clinical Collaboration | United States |
| Avant Diagnostics, Inc., Elto Pharma, Inc. | Undisclosed | Under the terms of the agreement, Amarantus agreed to cancel all liabilities (approximately $722,500) Avant owed to Amarantus and issue Avant 1,000,000 shares of Amarantus common stock. Avant agreed to issue to Amarantus an additional 30,092,073 Avant common shares in satisfaction of certain amounts owed under the original acquisition agreement. Amarantus intends to assign diagnostic assets (LymPro Test, MSPrecise and NuroPro) to a new subsidiary that aligns with Amarantus' holding company busi | Amarantus Bioscience Holdings, Inc. | Asset Re-acquisition | United States |
| Pharmacogenomics (PGx) Center of Excellence, University of Pittsburgh | Undisclosed | The new center will feature Thermo Fisher's portfolio of PGx testing solutions, including its PharmacoScan platform, to study preemptive panel-based PGx testing and return results in at least 150,000 patients in western and central Pennsylvania. | Thermo Fisher Scientific | Funding | United States |
| Pear Therapeutics | Undisclosed | Deal includes reSET®, cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O™, potential treatment pending FDA clearance for patients with Opioid Use Disorder treated with buprenorphine. Combines Sandoz expertise in launching / commercializing treatments with Pear's expertise in developing prescription digital therapeutics. Sandoz and Novartis continue to embrace emerging digital technologies to enhance R&D and deliver better outcomes for patients. | Sandoz (Novartis) | Development and Commercialization Agreement | United States |
| Topas Therapeutics GmbH | Undisclosed | Companies join forces in immune tolerance to tackle ADA (anti-drug antibodies) | Boehringer Ingelheim | Multi-year Collaboration | Germany |
| PSC Biotech | Undisclosed | LSNE-Madison is a 37,000 square foot multi-product facility that will be used for the manufacturing of final drug products for pre-clinical to Phase III/commercial use. The facility currently includes a high speed, automated aseptic fill line and a 144-square foot lyophilizer with existing space for additional equipment and the ability to expand to over 100,000 square feet of production space over time. This new facility will also increase LSNE's capabilities to include the terminal sterilizati | Lyophilization Services of New England (LSNE) | Acquisition | United States |
| Medical University of Vienna | Undisclosed | The company today also announced its partnership with the Medical University of Vienna for a 3-day pollen forecast on the Air Matters app, which retrieves its data from global pollen measurement sites, including the new measurement station at Philips’ Drachten site in the Netherlands | Royal Philips | Partnership | Austria |
| Baliopharm AG | Undisclosed | The transaction complements Promethera’s pipeline with an innovative antibody-based drug candidate that specifically binds to the tumor necrosis factor receptor 1 (TNF-R1). | Promethera Biosciences SA | Acquisition | Germany |
| New Jersey Urology, LLC | Undisclosed | The newly-formed organization will create the largest group of urologists in the United States, with 96 providers in 46 locations across the state of New Jersey, including 4 Cancer Treatment Centers. | Delaware Valley Urology, LLC, Bloom Organization | Merger Agreement | United States |
| Cardiologic Ltd. | Undisclosed | The autoRIC® device automatically delivers remote ischemic conditioning (“RIC”) to provide a non-invasive, cardio-protective therapy shown to reduce heart damage during heart attacks and certain cardiovascular procedures. The technology is CE Marked, and Health Canada approved, and is currently limited to investigational use in the United States. | CellAegis Devices Inc. | Distribution Agreement | United Kingdom |
| Ciel Medical, Inc. | Undisclosed | Vyaire management sees the acquisition of Ciel Medical as a step toward the company’s stated goal of becoming the global leader in the respiratory care market. | Vyaire Medical | Acquisition | United States |
| Acutronic Medical Systems, IMTmedical | Undisclosed | Acquires Acutronic Medical Systems and agrees to acquire IMTmedical | Vyaire Medical | Acquisition | Switzerland |
| Broad Institute of MIT and Harvard | Undisclosed | CRISPR-Cas9 commercial research tool technology acquired from Broad Institute will be used to build preclinical model animals and target treatment function analysis to further gene treatment research and development. | Macrogen, Inc. | License Agreement | United States |
| DIAN Diagnostics Group, Co., Ltd., F. Hoffmann-La Roche Ltd | Undisclosed | DIAN, a leader in the development and supply of Chinese medical diagnostic products and services, becomes the exclusive clinical sequencing partner in China for FoundationOne®, FoundationACT® and FoundationOne®Heme, enabling the delivery of personalized cancer care for patients. Roche maintains commercial exclusivity for Foundation Medicine’s molecular information products in China, and in cooperation with DIAN continues its current in-county activities to support the broad integration of CGP in | Foundation Medicine, Inc., | Three-Party Collaboration | China |
| California Department of Public Health | Undisclosed | The cGMP facility has a dedicated mRNA production area for the manufacture of cGMP-compliant mRNAs. In addition to supporting iPSC reprogramming efforts, cGMP mRNA will support ongoing internal development programs to generate iPSC derived cells. Current efforts are focused on the development of pancreatic beta cells, neurons, oligodendrocytes and their progenitor cells, hepatocytes, muscle cells, and mesenchymal cells. | Allele Biotechnology & Pharmaceuticals Inc. | License Agreement | United States |
| Codexis, Inc. | Undisclosed | The partnership will accelerate the creation and commercialization of new, low-cost, sustainable manufacturing processes, exploiting the benefits of biocatalysts to a growing number of the world’s small molecule pharmaceuticals. | Porton Pharma Solutions, Ltd. | Collaboration | United States |
| ReForm Biologics | Undisclosed | As part of the collaboration, KBI will provide services to ReForm to further develop and validate its biologic formulation platform while also gaining access to ReForm’s proprietary technology. Reform will maintain the ability to utilize its formulation technologies directly with its pharmaceutical and biotechnology partners. Financial terms of the agreement were not disclosed. | KBI Biopharma, Inc., Phoenix Venture Partners | Equity Financing | United States |
| Medidata | Undisclosed | The agreement will result in the NHMRC Clinical Trial Centre consolidating multiple electronic data capture (EDC) solutions to the Medidata eClinical platform. This includes the use of Medidata Rave eCOA/ePRO and Medidata Rave EDC, which enable the NHMRC Clinical Trials Centre to manage and ingest the widest array of clinical trial data, with the potential to include sensors, mobile apps, genomics and RWE (Real World Evidence). | National Health and Medical Research Council Clinical Trial Centre (NHMRC CTC) | Partnership | United States |
| Polyphor | Undisclosed | Polyphor today announced that it has successfully completed its Wellcome Trust collaboration which supported the development of novel Outer Membrane Protein Targeting Antibiotics (OMPTA) addressing the most resistant Gram-negative bacterial pathogens including those designated as a critical concern by the World Health Organization (WHO). | | Grants & Awards | Switzerland |
| QurAlis Corporation | Undisclosed | QurAlis is developing three precision therapies targeting three distinct subtypes of ALS: a drug to restore a dysfunctional cellular waste clearance system that progressively poisons neurons; a drug to treat overactive neurons and prevent cell death via excitotoxicity; and a transformative device to remove toxic proteins. | MP Healthcare Venture Management (MPH) | Seed Capital | United States |
| Ubiquigent Limited | Undisclosed | The collaboration builds on an existing long term relationship between the parties whereby FORMA has accessed Ubiquigent’s DUBprofiler™ platform for the screening of test compounds. This expanded partnership agreement brings together the strengths of both parties and leverages Ubiquigent’s chemistry and biology platforms to design novel DUB inhibitors. | FORMA Therapeutics | Strategic Alliance | United Kingdom |
| Morphotek®, Inc. (Eisai Inc.) | Undisclosed | The licensing agreement includes an upfront payment, milestones and sales royalty payments, which are undisclosed. BlissBio has an exclusivity option to expand the territory beyond China to the global market and to develop therapeutic ADCs to two additional undisclosed oncology targets. | Bliss Biopharmaceutical Co., Ltd. (BlissBio) | License Agreement | United States |
| Change Healthcare | Undisclosed | Netsmart innovates electronic health records (EHRs), solutions and services that are powerful, intuitive and easy-to-use. Our platform provides accurate, up-to-date information which is easily accessible to care team members in behavioral health, care at home, senior living and social services. | Netsmart | Acquisition | United States |
| Change Healthcare | Undisclosed | In a first for the telemedicine market, Doctor On Demand, a leading video medicine provider serving health plans, enterprise customers, and the direct-to-consumer market, is now using the Change Healthcare Intelligent Healthcare Network? to empower consumers to choose the most convenient and cost-effective lab for tests ordered by network physicians. | Doctor On Demand | Collaboration | United States |
| Syntekabio | Undisclosed | Yuhan Corporation said on Monday that it has signed a memorandum of understanding with Syntekabio to promote joint research on discovering biological markers or indicators of certain biological condition by analyzing patients’ genome properties and searching for new drug candidate materials using an AI-based platform. | Yuhan Corporation | Research Collaboration | South Korea |
| STA Pharmaceutical Co., Ltd (WuXi AppTec) | Undisclosed | PMD-026 is the first RSK inhibitor to demonstrate potential disease-modifying properties in triple-negative breast cancer (TNBC) | Phoenix Molecular Designs (PhoenixMD) | Manufacturing Agreement | China |
| Avizia | Undisclosed | This acquisition will bring to American Well a comprehensive acute care capability, including the best in class hospital-based cart lineup and custom software workflows for more than forty clinical specialties, including telestroke and tele-behavioral health. | American Well® | Acquisition | United States |
| Astellas Pharma Inc. (Agensys Research Facilities) | Undisclosed | Antibody-Drug Conjugate (ADC) research was the core focus of work conducted at Agensys. Astellas will continue certain clinical trials and collaborationsnon some ADC programs that have been in progress at Agensys, including its collaboration with Seattle Genetics, Inc. | Kite (Gilead Sciences) | Asset Transfer Agreement | Japan |
| NuProbe Global | Undisclosed | New molecular strategy enriches multiple disease-related rare genetic DNA variants with high accuracy in a single assay to enable personalized diagnosis and treatments | Wyss Institute at Harvard University | License Agreement | United States |
| Flowsion A/S | Undisclosed | The grant was awarded to assist in the development of an innovative automatic blood glucose control system, Glucostat, developed by Flowsion. Glucostat is expected to reduce mortality, morbidity, length of stay and treatment costs dramatically for intensive care patients compared to existing technologies. | European Commission Horizon 2020 SME Instrument | Grants & Awards | Denmark |
| Grid Therapeutics, LLC | Undisclosed | Grid’s Series B financing was led by Milestone Holdings, a California-based venture company boasting a strong history of identifying and funding companies developing disruptive technologies with revolutionary intellectual property, Paul Funk, a veteran software entrepreneur and founder of Funk Software, and Jeffery “TJ” Heyman, Founder and Chief Investment Officer of Woodbourne Capital Management International. | Milestone Holdings | Series B Financing | United States |
| Enterprise Therapeutics | Undisclosed | The funding will be used to support pioneering research, leveraging Enterprise Therapeutics’ bronchosphere technology platform. Bronchospheres are a miniaturised model of the human airway. This innovative model can be used to support high-throughput drug and target discovery and will be used to facilitate the development of new classes of therapeutics for the treatment of cystic fibrosis. | Cystic Fibrosis Trust | Financing | United Kingdom |
| Nordion® (Sotera Health LLC) | Undisclosed | Through the agreement, BWXT will acquire essentially all of Nordion’s medical isotope assets, including the radiochemical operation and contract manufacturing services in Kanata, and the medical isotope operation in Vancouver, British Columbia. | BWX Technologies, Inc. | Asset Purchase Agreement | United States |
| University of Oxford | Undisclosed | EMPA-KIDNEY will include approximately 5,000 people with established chronic kidney disease, with and without diabetes. The primary outcome of the study is to assess the effect of empagliflozin on time to clinically relevant kidney disease progression or cardiovascular death. The study will be part of the empagliflozin clinical development programme, the largest clinical development programme of an SGLT2 inhibitor. | Eli Lilly and Company, Boehringer Ingelheim | Clinical Collaboration | United Kingdom |
| Fujifilm Kyowa Kirin Biologics | Undisclosed | Under the terms of the agreement between two companies, Fujifilm Kyowa Kirin Biologics grants Mylan an exclusive license to commercialize the adalimumab biosimilar in Europe and will receive an up-front fee. In addition, Fujifilm Kyowa Kirin Biologics is eligible to receive a subsequent commercialization milestone payment and sales royalties. Mylan will be responsible for the sales activity of the product in European countries. The two companies continue to negotiate for commercializing the prod | Mylan N.V. | License Agreement | Japan |
| Rubicon Pharmacies Canada Inc. | Undisclosed | TorQuest Partners, one of Canada's leading mid-market private equity firms, is the majority shareholder of Amenity. | Amenity Holdings Inc. | Merger Agreement | Canada |
| Pure Sunfarms (Village Farms International Inc.) | Undisclosed | Pure Sunfarms’ objective is to be a vertically integrated supplier and in addition to production ramp-up is focused on senior management hires, downstream product development, and development of distribution and marketing strategies. With its options on two adjacent operational greenhouse facilities of 1.1 million ft2 and 2.6 million ft2, Pure Sunfarms’ potential production footprint of 4.8 million ft2 in one contiguous complex would be the largest cannabis cultivation site in Canada and the wor | Emerald Health Therapeutics | Supply Agreement | Canada |
| Magenta Therapeutics | Undisclosed | Last May, Be The Match BioTherapies announced its participation in Magenta’s Series B financing round and launched a strategic partnership to support the company’s efforts to address significant needs across all aspects of transplant medicine. The collaboration between Be The Match BioTherapies and Magenta leverages a wide range of Be The Match BioTherapies’ assets and services, including an extensive network of transplant centers and cord blood banks, as well as expertise in research protocols, | Be The Match BioTherapies | Series C financing | United States |
| Synthace Limited | Undisclosed | Analytica 2018 attendees will get a sneak peak of Antha software integrated with PIPETMAX®, a collaboration between Gilson and Synthace launching this summer. The software connects Gilson’s automated liquid handling platform, PIPETMAX, to the cloud and will make it easier to design and reproduce experiments. | PIPETMAX (Gilson, Inc.) | Collaboration | United Kingdom |
| Caris Life Sciences | Undisclosed | Caris Molecular Intelligence® is a patented and proprietary service that uses a combination of technologies, including Next-Generation Sequencing (NGS), to examine each tumour at the various biological stages of cancer, which provides individualised data about a patient's cancer. This information enables oncologists to make informed treatment decisions based on the unique molecular characteristics of each patient's cancer. | Mundipharma GmbH | Partnership | United States |
| Pennsylvania State University | Undisclosed | This long-term relationship will support the education and preparation of the next generation of biotechnology leaders. Part of Sartorius’ investment will be to enhance the Fermentation Facility that will play a significant role in Penn State’s Center of Excellence in Industrial Biotechnology (CoEIB). Sartorius will provide state-of-the-art fermentation technologies, and a central laboratory within the Fermentation Facility will be named the Sartorius Fermentation Gallery. | Sartorius Stedim Biotech SA | Partnership | United States |
| 4D Molecular Therapeutics (4DMT) | Undisclosed | The expanded agreement will allow each company to leverage its primary strengths to bring highly-optimized gene therapeutics to ophthalmology patients as expeditiously as possible. 4DMT will be responsible for vector discovery and optimization, product design and engineering, pre-clinical and early-stage clinical development, including manufacturing activities, while Roche will conduct pivotal clinical trials and commercialize the new therapeutics globally. | F. Hoffmann-La Roche Ltd | Expansion of Research Agreement | United States |
| ProBioGen AG | Undisclosed | Under the terms of the agreement, ProBioGen is developing a stable cell line, followed by process development and GMP clinical manufacturing for Tizona’s lead antibody drug candidate. | Tizona Therapeutics | Contract Development Agreement | Germany |
| American Association for Cancer Research | Undisclosed | nThe alliance will build trans-Atlantic collaborations by establishing training and exchange programs, catalyzing scientific innovation by convening international meetings and workshops, and uniting the community to influence global research policy, among other important topics. | Cancer Research UK | Strategic Alliance | United States |
| Rosetta Genomics | Undisclosed | Genoptix, Inc., a leading oncology diagnostic laboratory today announced that Rosetta Genomics’ stockholders have approved the acquisition of Rosetta Genomics by Genoptix. Genoptix will immediately begin marketing, selling and distributing the complete Rosetta Genomics portfolio and will ensure the uninterrupted availability of these important products for physicians and patients. Genoptix previously purchased Rosetta Genomics’ precision diagnostics (PDx) business in March 2018. Genoptix is a po | Genoptix, Inc. | Acquisition | United States |
| Lombard Medical Operations | Undisclosed | Concurrent with the UK administration process, parent company Lombard Medical, Inc. will be formally liquidated through a liquidator appointed by the Grand Court of the Cayman Islands and subsequently dissolved. There will be no recovery of any monies for any unsecured creditors or equity holders of Lombard Medical, Inc. in the Cayman liquidation. | MicroPort Scientific Corporation | Acquisition | United Kingdom |
| Catheter Research Inc. (CRI) Medical | Undisclosed | CRI is a manufacturer of interventional catheters, tube sets, and other assemblies for medical devices with expertise in tube extrusion, catheter assembly, final FDA product packaging for sterilization. CRI services OEM customers as well as sell their own catheter line under the brand Thomas Medical. | Biomerics ATL, LLC | Acquisition | United States |
| Freenome | Undisclosed | By decoding cell-free (cf) biomarker patterns of once unthinkable complexity, ?Freenome?'s artificial intelligence (AI) genomics platform is poised to detect cancer at its earliest stages and help clinicians optimize the next generation of precision therapies. | Biognosys | Partnership | United States |
| SPI Pharma | Undisclosed | The agreement will focus on finished dosage products for licensing to customers through dossiers developed by SPI Pharma for implementation by generic and branded pharmaceutical companies. Neither Noramco nor SPI has any intention to produce or market finished dosage forms. | Noramco | License Agreement | United States |
| NX Development Corp (NXDC) | Undisclosed | GleolanTM is an FDA-approved optical imaging agent indicated in patients with glioma [suspected World Health Organization (WHO) Grades III or IV on preoperative imaging] as an adjunct for the visualization of malignant tissue during surgery. | photonamic GmbH & Co. KG | Acquisition | United States |
| Lexi Pharma Inc | Undisclosed | Altum Pharmaceuticals Inc. (“Altum” or “Altum Pharmaceuticals”) announced today that it has completed the acquisition of Lexi Pharma Inc. (“Lexi Pharma”), a Canadian pharmaceutical company focused on the development of AP-002, a new chemical entity (NCE) small molecule with an active US FDA IND (Investigational New Drug application). AP-002, is a novel molecule, that selectively targets bone resorption while also demonstrating anti-tumor activity. Preclinical studies have shown that AP-002 selec | Altum Pharmaceuticals Inc. | Acquisition | Canada |
| National Center for Cardiovascular Diseases | Undisclosed | As a response to this national epidemic, the collaboration will (a) Evaluate the health economic consequences of diabetes in China. (b) Develop a simple cardiovascular disease (CVD) risk calculator to improve screening and diabetes management at the primary care level. (c) Analyze patient samples to identify new biomarkers for diabetes progression, diabetic kidney diseases (DKD), and CVD. Develop and distribute medical education for health care professionals treating diabetes related CVD in Chin | Eli Lilly and Company | R&D Collaboration | China |
| Bristol-Myers Squibb Company | Undisclosed | Under the agreement, Janssen Pharmaceuticals, Inc. and Bristol-Myers Squibb Company will advance BMS-986177 into Phase 2 clinical trials and establish a broad development program across multiple therapeutic indications. | Janssen Pharmaceutica NV | Collaboration | United States |
| UCSD School of Medicine’s Center for Medicinal Cannabis Research (CMCR) | Undisclosed | INSYS has agreed to provide its pharmaceutical-grade CBD oral solution—already under clinical evaluation in company-sponsored trials for treatment of refractory pediatric epilepsies—for this CMCR study, which is scheduled to start in 2019. | INSYS Therapeutics | R&D Collaboration | United States |
| Prayog Labs LLC | Undisclosed | This novel delivery has the potential to provide a non-addictive treatment option for acute pain that patients may experience, for example, during dentistry procedures, post-surgery and with orthopedic defects. Meloxicam also is proposed to treat chronic pain. | Mylan N.V. | License Agreement | United States |
| Jenner Institute of Oxford University | Undisclosed | Through collaboration with the Jenner Institute, partners will improve the process of developing adenovirus vaccines, vaccines based on adenoviruses - a type of DNA virus - using Merck products, systems and technologies, through continuous supply in the environment of a real practice Applying Merck technology, collaborators seek to develop a cost-effective and transferable process that can be used to accelerate the development and development of vaccines worldwide. | Merck Group | Research Agreement | United Kingdom |
| ViaCyte, Inc. | Undisclosed | In addition to having the only islet cell replacement therapies in clinical-phase testing, ViaCyte continues to advance the field of differentiating pluripotent stem cells, including induced pluripotent stem cells, to optimize these therapies for type 1 diabetes and insulin-requiring type 2 diabetes. ViaCyte’s multipronged approach also includes engineering its well-characterized, regulatory-compliant CyT49 pluripotent stem cell line to be immune-evasive, which, if successful, would open up of | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH) | Grants & Awards | United States |
| BioSig Technologies, Inc. | Undisclosed | Headquartered in New York, and with key offices in Los Angeles, Washington, DC and Geneva Switzerland, High Lantern Group is a leading positioning, public affairs and communication firm with a deep understanding of the global healthcare arena from both a business and a policy perspective. HLG counts some of the world’s top healthcare and technology companies among its clients, and it has spearheaded the creation and success of several global coalitions, including the Global CEO Initiative on Alz | High Lantern Group (HLG) | Partnership | United States |
| Applied BioMath | Undisclosed | Their Model-Aided Drug Invention (MADI) approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through clinical trials. The Applied BioMath team leverages their decades of expertise in biology, mathematical modeling and analysis, high-performance computing, and industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, patients, and the best path forward into and in t | Pandion Therapeutics | Collaboration | United States |
| Applied BioMath, LLC | Undisclosed | Applied BioMath, the industry-leader in applying mechanistic modeling to drug research and development, today announced a collaboration with Sanofi for the analysis of systems pharmacology pharmacokinetic (PK)/target engagement (TE) models for bispecific antibody combinations. Applied BioMath will help assess the risk and feasibility of multispecific combinations and compare them to fixed dose combinations (FDC) for multiple targets. These analyses will be used to help prioritize the portfolio a | Sanofi | Collaboration | United States |
| Applied BioMath, LLC | Undisclosed | In this collaboration, Applied BioMath will leverage MADI to predict optimal dosing regimens for Checkpoint Therapeutics' product candidates based on in vitro functional, in vivo efficacy, and preclinical toxicology data, as well as Phase 1 PK data. | Checkpoint Therapeutics | Collaboration | United States |
| Applied BioMath, LLC | Undisclosed | The collaboration will focus on developing a mathematical model relating XmAb®24306 modulated potency and extended half-life to observed pharmacokinetics and in vivo T-cell stimulation. Such models can guide preclinical and clinical development of new biologic agents such as XmAb24306. | Xencor | Collaboration | United States |
| Amneal Pharmaceuticals, LLC, Impax Laboratories, Inc. | Undisclosed | Upon closing the transaction, ANI will acquire a product portfolio consisting of five approved generic ANDAs and one pipeline product, Erythromycin IR tablets; ANI will also acquire a license, supply and distribution agreement for a second pipeline product, Diclofenac-Misoprostol DR tablets, with a pending ANDA. | ANI Pharmaceuticals, Inc. | Asset Purchase Agreement | United States |
| Q-State Biosciences | Undisclosed | In the collaboration, Q-State will use its proprietary drug discovery platform to develop novel cell-based assays that the companies will use to identify compound candidates. The Q-State platform combines cutting edge technologies that use induced pluripotent stem cells (iPSCs) to mimic disease in cells and a unique Optopatch™ all-optical electrophysiology system to measure differences between normal and diseased nerve cells. | Vertex Pharmaceuticals Inc. | Collaboration | United States |
| Stellar Biotechnologies, Inc. | Undisclosed | At the effective time of the reverse share split, every seven shares of Stellar Biotechnologies common shares will be combined into one common share of Stellar Biotechnologies. The reverse share split, known as a share consolidation under applicable British Columbia law, does not affect any shareholder's ownership percentage of the company's common shares or proportional voting power, except to the extent that the share consolidation would result in any fractional shares. | | Share Consolidation | United States |
| Sempre Health | Undisclosed | The two companies are seeking to engage 10,000 patients with diabetes on the Sempre Health platform in 2018. | Novo Nordisk A/S | Collaboration | United States |
| SAMDI Tech, Inc. | Undisclosed | Using its label-free and high-throughput SAMDI assay, the team at SAMDI Tech can screen a client’s target against any number of compounds. As hits are found, Enamine provides support with the follow-up chemistry needed to validate and optimize the compound’s activity. | Enamine | Partnership | United States |
| MAGiQ Therapeutics, Inc. (ReproCell) | Undisclosed | MAGiQ is a 50:50 joint venture, in which Q Therapeutics will contribute its patented technology to derive and manufacture glial-restricted progenitor (GRP) cells from any tissue source, including iPSC. REPROCELL will support manufacturing process development of iGRPs through to completion of proof-of-concept clinical trials in addition to providing integration-free, virus-free and clinically relevant human iPSC lines using proprietary RNA reprogramming technology. | Q Therapeutics, Inc., | Joint Venture | United States |
| Total Scientific Ltd | Undisclosed | RxCelerate, which has offices in Cambridge, MA and Cambridge, UK, provides bespoke drug development services to clients ranging from virtual biotech companies to global pharmaceutical giants. Its unique model is built around out-sourcing drug development expertise rather than practical experimental work, allowing RxCelerate to guide projects from discovery through to the clinic as efficiently as possible. | RxCelerate Ltd | Acquisition | United Kingdom |
| AllianceRx Walgreens Prime | Undisclosed | The new drugs treat rare conditions such as Huntington's disease, severe asthma and cystic fibrosis (CF), or offer improved treatment protocols for hemophilia in adults and children. | Prime Therapeutics LLC | Accessibility Agreement | United States |
| Oliver™ Suzhou Manufacturing Facility | Undisclosed | In this facility, all manufacturing will occur within an ISO-7 certified clean room environment, and product capabilities include pouch making, roll stock converting (including slitting and printing), die-cut lid manufacturing, and mounting card production. | Oliver Healthcare | Manufacturing Investment | China |
| Q-State Biosciences | Undisclosed | The collaboration calls for Q-State to build disease models using stem cell-derived neurons from epilepsy patients that can be employed with Q-State’s proprietary Optopatch technology. Optopatch permits the fine interrogation of neuronal networks by optical stimulation and recording and identifies the deficits in neuronal activity caused by genetic mutations. By coupling this platform with neuronal cell lines derived from epilepsy patients, the collaboration aims to characterize neuronal and ne | UCB | Research Collaboration | Belgium |
| Evotec AG | Undisclosed | Evotec will leverage its highly skilled experts across all disciplines, primarily oncology, to implement a tailored drug development strategy for Petra-01 and will receive undisclosed research funding and success-based milestones. | Petra Pharma Corporation | Collaboration | Germany |
| Technical University of Denmark’s Department of Chemistry (DTU Chemistry) | Undisclosed | The partnership includes workshops, special training sessions and project assignments, and as part of the program the students will get the opportunity to work directly with innovation and research in several ways: they will be working on their own projects in DTU Skylab’s laboratories, and they will get a unique opportunity to work on an ongoing research project with LEO Pharma. | LEO Pharma A/S | Partnership | Denmark |
